Cargando…

Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model

PURPOSE: To evaluate gadolinium (Gd) retention and clearance in the brain of diabetic rats after administrations of gadodiamide, gadopentetate dimeglumine, and gadoterate meglumine. MATERIALS AND METHODS: Both diabetic rats (n = 52) and normal rats (n = 52) intravenously received 20 injections of 0....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shu-ting, Hua, Zheng-xu, Fan, Dong-xiao, Zhang, Xin, Ren, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525955/ https://www.ncbi.nlm.nih.gov/pubmed/31192255 http://dx.doi.org/10.1155/2019/3901907

Ejemplares similares

Comprehensive Speciation Analysis of Residual Gadolinium in Deep Cerebellar Nuclei in Rats Repeatedly Administered With Gadoterate Meglumine or Gadodiamide
por: Strzeminska, Izabela, et al.
Publicado: (2022)

Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine, and Gadobutrol to rats
por: Bussi, Simona, et al.
Publicado: (2021)

Comparison of Gadopentetate dimeglumine and Gadobenate dimeglumine in depiction of non-ischemic fibrosis in hypertrophic cardiomyopathy
por: Rudolph, Andre, et al.
Publicado: (2009)

Neurotoxic Manifestations of an Overdose Intrathecal Injection of Gadopentetate Dimeglumine
por: Park, Kwan-Woong, et al.
Publicado: (2010)

Single dose gadobenate dimeglumine for imaging chronic of myocardial infarction in comparison to double dose gadopentetate dimeglumine
por: Bauner, Kerstin U, et al.
Publicado: (2009)

Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats
por: Fretellier, Nathalie, et al.
Publicado: (2019)

Anaphylaxis to gadobutrol and gadoterate meglumine in a patient with low grade astrocytoma
por: Montalvo, Juan Manuel Escobar, et al.
Publicado: (2014)

Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study
por: Chang, De-Hua, et al.
Publicado: (2019)

Comparison of gadoxetic acid and gadopentetate dimeglumine-enhanced MRI for HCC detection: prospective crossover study at 3 T
por: Besa, Cecilia, et al.
Publicado: (2015)

A case report of gadopentetate dimeglumine‐induced cardiac arrest: Resuscitation using extracorporeal membrane oxygenation
por: Fang, Honglong, et al.
Publicado: (2023)

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure
por: Davies, Julie, et al.
Publicado: (2021)

Different Impact of Gadopentetate and Gadobutrol on Inflammation-Promoted Retention and Toxicity of Gadolinium Within the Mouse Brain
por: Anderhalten, Lina, et al.
Publicado: (2022)

Correlations from gadopentetate dimeglumine-enhanced magnetic resonance imaging after methotrexate chemotherapy for hemorrhagic placenta increta
por: Wehbe, Salim A, et al.
Publicado: (2003)

Gadoterate meglumine decreases ADC values of breast lesions depending on the b value combination
por: Arponen, Otso, et al.
Publicado: (2018)

Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study
por: Soyer, Philippe, et al.
Publicado: (2016)

Long-Term Treatment with Gadopentetic Acid or Gadodiamide Increases TRPC5 Expression and Decreases Adriamycin Nuclear Accumulation in Breast Cancer Cells
por: Zhang, Weiheng, et al.
Publicado: (2023)

Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T
por: Clauser, Paola, et al.
Publicado: (2018)

Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI
por: Lim, Jiyeon, et al.
Publicado: (2018)

Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats
por: Habermeyer, Johanna, et al.
Publicado: (2020)

A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years
por: Scala, Mario, et al.
Publicado: (2018)

Lack of nephrotoxicity of gadopentetate dimeglumine-enhanced non-vascular MRI and MRI without contrast agent in patients at high-risk for acute kidney injury
por: Oguz, Ebru Gok, et al.
Publicado: (2013)

Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children
por: Lancelot, Eric, et al.
Publicado: (2017)

Gadolinium retention and clearance after administration of macrocyclic magnetic resonance contrast agents to rats
por: Bussi, Simona, et al.
Publicado: (2019)

CEMRA in neonatal and pediatric congenital vascular diseases at 1.5T and 3.0T: comparison of an intravascular contrast agent (Gadofosveset) with an extracellular agent (Gadopentetate Dimeglumine)
por: Khan, SN, et al.
Publicado: (2013)

CEMRA in neonatal and pediatric congenital vascular diseases at 1.5T and 3.0T: comparison of an intravascular contrast agent (Gadofosveset) with an extracellular agent (Gadopentetate Dimeglumine)
por: Khan, Sarah N, et al.
Publicado: (2013)

Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017)
por: Ding, Ying, et al.
Publicado: (2018)

Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging
por: Krug, Kathrin Barbara, et al.
Publicado: (2021)

Re: Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients
por: Raynaud, Jean-Sébastien, et al.
Publicado: (2018)

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)
por: Deray, Gilbert, et al.
Publicado: (2012)

Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle
por: Glessgen, Carl Guillaume, et al.
Publicado: (2021)

Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging: Results of a Post-Marketing Surveillance Study in Japan
por: Ishiguchi, Tsuneo, et al.
Publicado: (2012)

Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine
por: Violas, Xavier, et al.
Publicado: (2022)

Gadolinium Retention in the Brain of Mother and Pup Mouse: Effect of Pregnancy and Repeated Administration of Gadolinium‐Based Contrast Agents
por: Yao, Xiang, et al.
Publicado: (2022)

Cochlear Lymph Fluid Signal Increase in Patients with Otosclerosis after Intravenous Administration of Gadodiamide
por: NAGANAWA, Shinji, et al.
Publicado: (2016)

The fate of Gd and chelate following intravenous injection of gadodiamide in rats
por: Kindberg, Grete Mørk, et al.
Publicado: (2010)

A Contrast Examination of Proinflammatory Effects on Kidney Function for γ-Fe(2)O(3) NP and Gadolinium Dimeglumine
por: Xie, Qian, et al.
Publicado: (2021)

Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents
por: Ringler, Michael D., et al.
Publicado: (2021)

Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals
por: Young, Laura K., et al.
Publicado: (2018)

Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
por: Thomsen, Henrik S.
Publicado: (2006)

Severe Adverse Drug Reaction to Gadobenate Dimeglumine
por: Singer, Benjamin D., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_i9qdd2opagngo5ovndonqm3dht